NCT07232953 (FT14) is a Phase 2 clinical trial of Fludarabine + Treosulfan in Acute Myeloid Leukaemia (AML), sponsored by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia.

Who is sponsoring NCT07232953?

NCT07232953 is sponsored by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia.

What drugs are being tested in NCT07232953?

Interventions in NCT07232953: Fludarabine + Treosulfan.

What condition does NCT07232953 study?

NCT07232953 studies Acute Myeloid Leukaemia (AML), Hematopoietic Stem Cell Transplant (HSCT).

Is NCT07232953 still recruiting?

NCT07232953 is currently active, enrolled. Last updated 16 November 2025.

Last reviewed 2025-11-16 · How we verify

NCT07232953: FT14

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Phase II Study on Safety and Efficacy of Fludarabine Plus Treosulfan (14g) (FT14) Conditioning Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Acute Myeloid Leukemia (AML) Patients (≥40 <65years) (FT14-Trial)

Active, enrolled Phase 2 Last updated 16 November 2025

What this trial tests

Phase 2 trial testing Fludarabine + Treosulfan in Acute Myeloid Leukaemia (AML) in 82 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

10 November 2022

Primary endpoint
1 June 2026

1 June 2027

Quick facts

Lead sponsor	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	82
Start date	10 November 2022
Primary completion	1 June 2026
Estimated completion	1 June 2027
Sites	13 locations across Italy

Drugs / interventions tested

Fludarabine + Treosulfan — full drug profile →

Conditions studied

Acute Myeloid Leukaemia (AML) — all drugs for Acute Myeloid Leukaemia (AML) →
Hematopoietic Stem Cell Transplant (HSCT) — all drugs for Hematopoietic Stem Cell Transplant (HSCT) →

Sponsor

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia — full company profile →

Who can join

Adults 40 to 65, any sex, with Acute Myeloid Leukaemia (AML) or Hematopoietic Stem Cell Transplant (HSCT). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The 1-year leukemia -free survival (LFS) after allo-SCT
Time frame: From allo-HSCT to 1-year post allo-HSCT
Proportion of patients alive and free from leukemia at 1 year after allogeneic hematopoietic stem cell transplantation (allo-HSCT), estimated using the Kaplan-Meier method.

Sponsor's own description

This is a prospective, multicenter, phase II, open-label, non-randomized clinical trial designed to evaluate the safety and efficacy of the Fludarabine plus Treosulfan 14 g/m² (FT14) conditioning regimen for allogeneic stem cell transplantation (allo-SCT) in patients with Acute Myeloid Leukemia (AML) aged 40-65 years who are in complete remission.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukaemia (AML)

Currently open trials in the same condition.

NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting
NCT07244367 — Maintenance Venetoclax in AML Fit Patients · NA · recruiting

Other Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia trials

Trials by the same sponsor.

NCT06493708 — Effectiveness of EMDR in Borderline Personality Disorder · NA · recruiting
NCT07370961 — Pilot Study to Evaluate the Impact of a Multidisciplinary Approach (Pharmacological and Psychological) in the Treatment · NA · completed
NCT05847387 — The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study · recruiting
NCT05738902 — Adherence and Compliance to ERAS in Gynecological Surgery · unknown
NCT06765343 — Efficacy of Guided Biofilm Therapy in Pediatric Patient · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07232953 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Last refreshed: 16 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07232953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing